Loading…
Combination therapy of hepatitis B
Another major problem with the design was the differences in the timing of the end point evaluation in relation to therapy. [...]the end points were measured in patients receiving lamivudine while they were still on treatment, but in those receiving interferon or the combination at a point six month...
Saved in:
Published in: | Gut 2000-04, Vol.46 (4), p.450-451 |
---|---|
Main Authors: | , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Another major problem with the design was the differences in the timing of the end point evaluation in relation to therapy. [...]the end points were measured in patients receiving lamivudine while they were still on treatment, but in those receiving interferon or the combination at a point six months after stopping therapy. [...]at the one year point, HBV DNA levels, aminotransferases and liver histology may well have been affected by the continuation of lamivudine therapy. |
---|---|
ISSN: | 0017-5749 1468-3288 1458-3288 |
DOI: | 10.1136/gut.46.4.450 |